Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06313541
Status:
RECRUITING
Last Update Posted:
2024-06-05
First Post:
2024-03-10
Brief Title:
Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Multicenter Randomized Controlled Clinical Trial of Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multicenter randomized controlled clinical trial to explore the preliminary efficacy and safety of treatment response adapted hybrid radiotherapy LDRT and SBRT in the first-line treatment of immunotherapy combined with chemotherapy for advanced driver-gene negative NSCLC and to provide new ideas for the comprehensive treatment of advanced NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None